MedTech Launch Guide
    Education Hub for Founders
    Live Tape· 42d ago
    In partnership with Blue Goat Cyber

    The pulse of MedTech capital, regulation & survival.

    Funding rounds decoded, pitch deck teardowns, cybersecurity budgets that pass FDA scrutiny, and the un-glamorous post-mortems behind 90% of MedTech failures. Built for founders and the investors who back them.

    Live data sources
    openFDA · CISA · ClinicalTrials.gov
    FDA cyber guidance
    Feb 3, 2026 final
    Refreshed
    Daily, automated
    A surgical instrument with an overlaid ECG waveform and financial chart lines
    From the guidance

    "FDA may refuse to accept a premarket submission that does not include the cybersecurity information described in this guidance."

    - FDA, Cybersecurity in Medical Devices, Feb 2026 final guidance
    § 01 - Capital Markets

    The rounds that moved the field this quarter.

    Live tape of recent MedTech funding - extracted from public news via Firecrawl + AI. Click refresh to pull the latest deals.

    Updated 5/4/2026, 2:17:59 PM
    Primer · what each round is actually buyingClick a stage to see its regulatory, clinical & commercial drivers

    Unlike SaaS, MedTech rounds aren't sized to revenue - they're sized to the next de-risking event (predicate confirmed, FIH read-out, FDA clearance, first paying hospital). Investors price the round based on what milestone the cash unlocks. Use this as a yardstick before benchmarking the live tape below.

    Quiz · what is each round actually buying?0/5 answered · 0 correct

    Five short scenarios - one per stage. Pick the answer you'd give a lead investor; miss one and the quiz drills into that stage with two follow-up questions before moving on.

    Tailor to your device category

    Pick one and every explanation below adds a category-specific milestone note. Change anytime.

    1. Q1 · Pre-Seed

      What milestone is a Pre-Seed round actually buying?

      Two clinician-founders, working bench prototype, no IP filed, raising $750K.

    2. Q2 · Seed

      A Seed lead asks: 'What does this $3M unlock?' What's the strongest answer?

      Class II software-as-a-medical-device, predicate already identified.

    3. Q3 · Series A

      Your Series A lead wants to see one specific deliverable in the data room. What is it?

    4. Q4 · Series B

      FDA clearance is in hand. What's the Series B failure mode that scares investors most?

    5. Q5 · Series C+

      What metric do crossover and growth investors scrutinize most at Series C+?

    Investor glossary · ten terms every medtech founder hears in their first pitchFull glossary →

    Capital and clearance vocabulary collide in medtech. These are the terms that decide whether a term sheet, a 510(k) plan or a board update lands the way you intended.

    Dilution
    Ownership %
    The reduction in existing shareholders' ownership percentage when new shares are issued. A $5M seed at a $20M post-money values founders' stock at 75% - that 25% is the dilution. Compounds across rounds; a typical medtech founder team holds 10–25% by Series B.
    De-risking milestone
    Why this round exists
    A specific, verifiable event that materially lowers technical, regulatory or commercial risk - and unlocks the next round at a higher valuation. Examples: predicate confirmed via Pre-Sub, FIH read-out, FDA clearance, first paid hospital deployment. Investors price rounds on what milestone the cash buys.
    Predicate
    FDA · 510(k)
    A legally marketed medical device that your 510(k) submission claims substantial equivalence to. Choosing a predicate determines your indication for use, performance testing burden and review timeline. The 'most cleared' predicate is rarely the most defensible one.
    eSTAR
    FDA submission format
    Electronic Submission Template And Resource - FDA's mandatory interactive PDF template for 510(k) submissions (and most De Novos). Built-in completeness checks reduce Refuse-to-Accept bounces. Not a software platform; a structured form you fill out and upload via the CDRH Customer Collaboration Portal.
    Pre-money / Post-money
    Valuation
    Pre-money is the company's value before new capital comes in; post-money is pre-money plus the new round. A $5M raise at $15M pre = $20M post, and the new investor owns 25% ($5M / $20M). Always confirm which one a term sheet quotes - the difference is real ownership.
    Pro-rata rights
    Follow-on protection
    Contractual right for an existing investor to participate in future rounds at the same proportional ownership. Most seed funds insist on it; aggressive Series A leads sometimes try to strip it. Matters because medtech requires multiple capital injections before clearance.
    Liquidation preference
    Exit waterfall
    The multiple of invested capital a preferred shareholder gets paid before common stock at exit. 1× non-participating is founder-friendly; 2× participating means investors take 2× their money plus their pro-rata share of the rest. Stacks across rounds - model the waterfall before signing.
    Burn multiple
    Capital efficiency
    Net cash burned ÷ net new ARR over the same period. Pre-revenue medtechs use a modified version: cash burned per de-risking milestone hit. Investors at Series B+ benchmark burn multiple to decide whether the next round is an extension or a step-up.
    Bridge round
    Between priced rounds
    Convertible note or SAFE raised between priced rounds - typically to extend runway to a missed milestone (FDA delay, slower-than-modelled enrollment). Often signals a down-round risk; sophisticated founders structure bridges with caps that protect against punitive conversion.
    Strategic vs financial investor
    Cap table mix
    Financial investors (VC, growth equity) optimise for IRR and exit. Strategics (J&J, Medtronic, Stryker venture arms) optimise for product line gaps and pre-emption. Strategics on the cap table early can deter competing acquirers later - useful sometimes, value-destroying others.
    Filter by stage
    Company Round Raised Lead Date
    AcuityMD
    AI-driven MedTech intelligence platform
    Series C $80M StepStone Group April 21, 2026
    Gravity Rail
    AI-powered patient engagement workflows
    Seed $2.75 million Redesign Health April 23, 2026
    WHOOP Inc.
    MedTech
    Series G $575 million - March 2026
    § 02 - Live Intelligence

    Eight signals, refreshed daily.

    FDA clearances, recalls, CISA medical advisories, clinical trial starts, M&A, founder sentiment, hiring trends, and public market prints - pulled from official APIs and curated news, refreshed every morning at 06:10 UTC.

    Public Tape
    ABT$84.32▼ 3.25%
    BDX$149.43▼ 2.88%
    BSX$53.93▼ 4.26%
    DXCM$60.61▼ 0.49%
    EW$79.96▼ 3.53%
    ISRG$450.06▼ 0.94%
    MDT$76.15▼ 2.80%
    SYK$285.47▼ 2.90%
    FDA recalls
    openFDA28d ago6
    BioFire Joint Infection (JI) Panel REF: RFIT-ASY-0138, 30 test Kit.
    BioFire Diagnostics, LLC - Contamination to in-vitro diagnostic test may result in false positives.
    2026-04-22
    Philips Achieva 1.5T with MR Elastography (MRE). 1. Model Number (REF): 781196. 2. Model Number (REF): 781296.
    Philips North America - The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction voxel size settings in the default MRE scan protocol displaying too small.
    2026-04-14
    Philips Achieva 1.5T Initial system with MR Elastography (MRE). 1. Model Number (REF): 781178.
    Philips North America - The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction voxel size settings in the default MRE scan protocol displaying too small.
    2026-04-14
    Philips Achieva 3.0T with MR Elastography (MRE). 1. Model Number (REF): 781278.
    Philips North America - The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction voxel size settings in the default MRE scan protocol displaying too small.
    2026-04-14
    Philips Evolution Upgrade 1.5T with MR Elastography (MRE). 1. Model Number (REF): 782116 2. Model Number (REF): 782148. 3. Model Number (REF): 782166.
    Philips North America - The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction voxel size settings in the default MRE scan protocol displaying too small.
    2026-04-14
    Philips Evolution upgrade 3.0T with MR Elastography (MRE). 1. Model Number (REF): 782143. 2. Model Number (REF): 782162.
    Philips North America - The potential for stiffness value errors when a specific range of image reconstruction parameters is used in combination with Resoundant's algorithm, leading to the reconstruction voxel size settings in the default MRE scan protocol displaying too small.
    2026-04-14
    CISA medical advisories
    CISA.gov0
    No new medical-device advisories this week
    New device trials
    ClinicalTrials.gov28d ago6
    Altius Peripheral Nerve Stimulation in Amputees After TMR/RPNI
    NYU Langone Health - Amputation; Lower Extremity, Pain, Persistent Postsurgical
    NA
    Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery
    The University of Texas Health Science Center, Houston - Hypersensitivity Reactions, Allergic Contact Dermatitis
    NA
    Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis.
    Assistance Publique - Hôpitaux de Paris - Amyotrophic Lateral Sclerosis, Charcot Disease
    PHASE1, PHASE2
    Biceps Femoris Short Head (BiFeS) Block and Adductor Canal Block for Postoperative Analgesia Following Total Knee Arthroplasty
    Ömer Kayar - Postoperative Pain Following Knee Arthroplasty, Total Knee Arthroplasty
    NA
    Impact of Continuous Glucose Monitoring and Education Intervention on Glycemic Control and Behavioral Changes in Pre-Diabetic Adolescents
    University of Arizona - Pre Diabetes
    2026-06-01
    AI-assisted Diagnosis, Triage and Assessment of Hearing Loss and Tinnitus
    Royal Cornwall Hospitals Trust - Hearing Loss, Adult-Onset, Tinnitus
    2026-05-30
    Founder & clinician chatter
    Firecrawl28d ago6
    Utah AI Startup Prescribes SSRIs Without Psychiatrist Oversight
    A new healthcare startup in Utah is using AI to prescribe SSRIs to patients, raising concerns due to the absence of psychiatrist oversight.
    LinkedIn
    Building a 'Billion Dollar' AI Healthcare Company with Zero Medical Background
    A discussion by a founder on how they built a successful AI healthcare company without a medical background, leveraging various tech platforms.
    LinkedIn
    Biotech rivalries and collaborations between the US and China
    The article discusses the complex relationship between the US and China in the biotech sector, highlighting both the competitive aspects and potential for collaboration.
    Cell & Gene Therapy Review
    Building a healthcare AI startup: from prototype to product
    A founder discusses the challenges of moving a healthcare AI product, focused on clinical reasoning and medico-legal documentation, from prototype to a real-world application.
    r/Bangalorestartups
    Is getting acquired the new IPO for biotech and healthcare founders?
    A discussion explores whether acquisition by larger companies is becoming the preferred exit strategy for biotech and healthcare founders, rather than an IPO.
    Instagram (skim.insights)
    San Francisco startups are pushing a hot peptide summer
    Startups in San Francisco are heavily investing in gray-market peptides, despite medical concerns and lack of FDA approval.
    SF Standard
    Sector benchmarks
    0
    We don't publish aggregate sector totals we can't verify. For benchmarks, see SVB Healthcare Investments & Exits, Rock Health, and CB Insights State of Digital Health. Live large-cap MedTech prints appear in the Public Tape strip above.

    Sources · openFDA · ClinicalTrials.gov · CISA · Stooq · Firecrawl + Lovable AI · Refreshed daily 06:10 UTC

    § 03 - Pitch Deck

    The 10-slide MedTech deck that closes.

    Synthesised from teardowns of 60+ MedTech decks that closed between $1.5M and $60M. Total run-time: under 8 minutes.

    View through the lens of
    Series A cyber line item
    $200K – $500K
    2–3% of raise

    "Our cybersecurity package is reviewer-ready. Submission risk is contained."

    Talking points
    • eSTAR cyber sections drafted: SBOM, threat model, SPDF, architecture views.
    • Pre-Sub on cyber complete - FDA feedback documented.
    • Hospital MDS2 questionnaire pre-filled to compress procurement cycles.
    Full stage budget →
    • Reverse-engineered from successful raises
    • Reviewed by ex-FDA reviewers
    • Mapped to Blue Goat security checklist
    Get the Figma template →
    1. 01

      The Clinical Problem

      Frame the unmet need with a real patient and a real number - incidence, mortality, cost burden.

      Series A

      Pair the patient story with bottom-up incidence × cost burden you've validated with KOLs.

      30s
    2. 02

      Solution & Mechanism

      Photo of the device. One sentence on how it works. Resist the urge to teach physiology.

      Series A

      Show the production-intent device + a diagram of the connectivity / data flow.

      Cyber angleOverlay a trust boundary on the data-flow diagram. Investors love seeing where PHI lives.
      45s
    3. 03

      Evidence to Date

      Bench data, animal data, first-in-human. Investors discount unsubstantiated claims by 80%.

      Series A

      First-in-human results + IRB-approved feasibility study readout.

      60s
    4. 04

      Regulatory Path

      510(k), De Novo, or PMA - with predicate device, expected timeline, and pre-sub history.

      Series A

      Pre-Sub feedback in hand. eSTAR-ready package in build.

      Cyber angleState that your eSTAR cyber sections (SBOM, threat model, SPDF) are drafted.
      45s
    5. 05

      Reimbursement Strategy

      CPT code path, payor conversations, and your number for cost-per-procedure savings.

      Series A

      Payor advisory board + economic model with 3 payor archetypes.

      60s
    6. 06

      Market Sizing - Bottom Up

      Procedures × ASP × penetration. Top-down TAMs get instantly dismissed.

      Series A

      Add geographic + indication-expansion layers with timing.

      45s
    7. 07

      Competitive Landscape

      2x2 with axes investors actually care about. Show the moat - IP, data, switching cost.

      Series A

      IP claims granted/pending. Data moat starting to compound.

      Cyber angleAdd a security-posture row: most incumbents still ship without an SBOM.
      30s
    8. 08

      Go-To-Market

      KOLs, IDN strategy, and the first 10 hospitals. Specificity wins.

      Series A

      First 10 target hospitals + which IDNs they belong to.

      Cyber angleMention the hospital MDS2 / HIPAA security questionnaire is pre-filled and ready.
      45s
    9. 09

      Team

      Ex-operators from the field you're disrupting. Highlight prior FDA clearances.

      Series A

      Full exec bench except CCO. Prior FDA clearances on the team.

      Cyber angleFractional CISO or named security lead. Cyber owner appears on the org chart.
      30s
    10. 10

      Financials & The Ask

      18-24 months of runway, milestones tied to value inflections, post-money expectation.

      Series A

      $8–20M to clearance + early commercial. Milestones tied to submission.

      Cyber angleBreak out the $200–500K cyber line tied to submission milestone.
      60s
    § 04 - Regulatory Strategy

    Pick the right FDA pathway, build the right evidence.

    510(k), De Novo, PMA, HDE, Breakthrough, Pre-Sub - each pathway has a different timeline, a different bar, and a different cybersecurity package. Synthesised from Blue Goat Cyber's regulatory playbook.

    Six routes to market

    All trigger Section 524B
    510(k)
    Premarket Notification
    3–9 mo· ~6 mo avg
    Best for

    Most Class II devices that are substantially equivalent to a legally marketed predicate.

    Examples

    Patient monitors, infusion pumps, connected wearables, imaging software (CADx).

    Cyber lift

    Section 524B applies in full. Reviewers expect SPDF evidence, machine-readable SBOM, threat model, and postmarket plan in the eSTAR.

    Fee: Standard / small-business user fees apply.
    De Novo
    Risk-Based Classification Request
    9–12+ mo· Establishes a new classification
    Best for

    Novel low-to-moderate-risk devices (Class I/II) with no valid predicate.

    Examples

    First-of-kind digital therapeutics, novel SaMD diagnostics, AI-enabled triage tools.

    Cyber lift

    Cyber expectations equal to 510(k); novelty draws extra reviewer attention to threat-model rigor and ML/AI threats.

    Fee: Higher than 510(k); small-business waivers available.
    PMA
    Premarket Approval
    12–24+ mo· Highest bar
    Best for

    Class III devices - those supporting/sustaining human life or presenting potential unreasonable risk.

    Examples

    Implantable cardiac devices, neurostimulators, life-supporting infusion systems, certain AI/ML diagnostics.

    Cyber lift

    Highest bar. Manual penetration testing, deep traceability (threat → requirement → design control → V&V), and an active CVD program are effectively required.

    Fee: Highest user-fee tier.
    HDE
    Humanitarian Device Exemption
    75-day review· After HUD designation
    Best for

    Devices for rare conditions affecting < 8,000 US patients/yr. Requires HUD designation first.

    Examples

    Pediatric implants for rare disorders, niche neuromodulation devices.

    Cyber lift

    Cyber requirements still apply. Connectivity profile + patient-safety impact drive evidence depth.

    Fee: Reduced.
    Breakthrough
    Breakthrough Devices Program
    Sprint reviews· Still goes through 510(k) / De Novo / PMA
    Best for

    Devices providing more effective treatment/diagnosis of life-threatening or irreversibly debilitating conditions.

    Examples

    Novel cancer dx, first-line stroke detection AI, BCI devices for paralysis.

    Cyber lift

    Speed does not relax cyber expectations. Build SPDF + threat model + SBOM in parallel - late additions cause schedule slips.

    Fee: Same as underlying pathway; benefits include sprint discussions and priority review.
    Pre-Sub
    Pre-Submission (Q-Sub)
    Free
    60–75 days· Written feedback + meeting
    Best for

    Getting written FDA feedback on your strategy before you file. Free and underused.

    Examples

    Used at concept, before pivotal study, before any pathway above.

    Cyber lift

    Best place to align on cybersecurity evidence depth, AI/ML threat scope, and acceptable VEX justifications before you commit to a build plan.

    Fee: Free.

    Class I, II, III - what changes for cyber

    Risk-based
    Class I
    Low risk
    Controls

    General controls (registration, listing, GMP, labeling).

    Typical pathway

    Most are 510(k)-exempt; some require 510(k).

    Cyber lift

    Section 524B still applies if the device meets the cyber-device definition. Even minimal connectivity (Bluetooth, USB sync) triggers full cyber expectations.

    Examples

    Bandages, manual stethoscopes, basic surgical instruments, some software accessories.

    Class II
    Moderate risk
    Controls

    General + special controls (performance standards, post-market surveillance, labeling).

    Typical pathway

    Typically 510(k); some De Novo.

    Cyber lift

    Default for connected medical devices. SPDF + machine-readable SBOM + threat model + pen test + postmarket plan all expected.

    Examples

    Infusion pumps, patient monitors, most SaMD, imaging software, connected diagnostics.

    Class III
    High risk / life-supporting
    Controls

    Premarket approval (PMA) - highest level of regulatory control.

    Typical pathway

    PMA (rarely HDE for rare-disease versions).

    Cyber lift

    Highest expectations. Reviewers want exhaustive traceability, manual exploit-driven testing, AI/ML threat coverage, and a mature CVD program.

    Examples

    Implantable defibrillators, neurostimulators, replacement heart valves, certain implantable AI systems.

    Cybersecurity artifact crosswalk

    When each artifact starts, iterates, ships
    Artifact Scope Classify Pre-Sub Evidence Test Submit Postmarket
    SPDF (Secure Product Development Framework) S
    Asset & Interface Inventory S
    Threat Model (STRIDE + Attack Trees) S
    Cybersecurity Risk Assessment (AAMI SW96) S
    Machine-Readable SBOM (CycloneDX 1.5) S
    Vulnerability Exploitability eXchange (VEX) S
    Security Architecture & Control Mapping S
    Penetration Test Report S
    Fuzz / Protocol Test Results S
    Cybersecurity Labeling (IFU) S
    Coordinated Vulnerability Disclosure (CVD) S
    Postmarket Cybersecurity Plan S
    S Start drafting Iterate / expand Finalize / submit

    The 5-step plan

    Sequencing regulatory + cyber

    The single biggest mistake: treating cybersecurity as a final-mile add-on. Every pathway above rewards teams that build evidence in parallel with engineering.

    1. STEP 01
      Confirm device classification

      Use the FDA product classification database and the MDCC crosswalk to confirm your product code, regulation number, and class. Class drives pathway, evidence depth, and timeline.

      FDA Product Classification DB
    2. STEP 02
      Decide pathway

      510(k) if a defensible predicate exists. De Novo if novel and low-to-moderate risk. PMA if Class III. Consider Breakthrough designation if eligible - file Q-Sub feedback before committing.

      FDA Breakthrough Devices Program
    3. STEP 03
      Map cybersecurity to the pathway

      Every pathway above triggers Section 524B cyber-device requirements. Build the SPDF, SBOM, threat model, and postmarket plan in parallel with engineering - not at the end.

      FDA 2026 Cybersecurity Guidance
    4. STEP 04
      Use a Pre-Sub to de-risk

      A Q-Sub is the cheapest reviewer feedback you'll ever get. Validate the cybersecurity scope, AI/ML threat coverage, and acceptable VEX justifications before you build evidence at scale.

      FDA Q-Sub Program
    5. STEP 05
      Build the eSTAR-ready package

      Cybersecurity risk assessment, threat model, SBOM (CycloneDX 1.5), pen test report, postmarket plan, labeling. Each artifact has a specific eSTAR slot.

      FDA eSTAR Templates
    Recommended tool
    MDCC Crosswalk

    Map FDA, EU MDR, IEC 62304, AAMI TIR57 and ISO 14971 in one view - essential for multi-jurisdiction submissions.

    Need a strategy session?
    Book a regulatory + cyber review

    30 minutes with a senior medical-device security engineer. We'll review your device profile, recommend the pathway, and identify the evidence you need.

    § 05 - Cybersecurity Budget · Sponsored by Blue Goat Cyber

    How much cyber budget to put in your raise.

    A stage-by-stage guide for connected Class II MedTech founders - drawn from Blue Goat Cyber's 250+ FDA submissions (100% success rate). Class III adds 30–50%; pure SaMD shaves ~20%.

    The short answer

    Allocate 2–5% of every round to cybersecurity through Series A - then transition to 1–2% of opex as a continuous postmarket program from Series B onward.

    Underspending here is the single most common reason FDA submissions stall - and the most expensive line item to backfill late.

    Round by round

    5 stages
    Pre-Seed
    Raise: $250K – $1.5M
    $15K – $40K
    3–5% of raise

    Concept validation, founding team, IP, early prototypes.

    What to buy
    • Architecture / threat-modeling working session
    • Initial cyber risk register tied to ISO 14971
    • Tech-choice review (connectivity, OS, crypto)
    • Pre-Sub (Q-Sub) cybersecurity strategy memo
    Skip

    Full pen test · SBOM tooling stack · dedicated CISO

    We've baked cybersecurity into our architecture before writing the first line of firmware - here's the threat model.

    Seed
    Raise: $1.5M – $5M
    $60K – $150K
    3–4% of raise

    MVP build, first clinical engagement, regulatory pathway lock-in.

    What to buy
    • STRIDE-per-element threat model + AAMI TIR57
    • First-pass SBOM (CycloneDX 1.5) + tooling
    • Pre-Sub submission with cybersecurity scope
    • Lightweight gray-box pen test of MVP
    • SPDF skeleton + SDLC integration
    Skip

    Full PSIRT · bug bounty · expensive GRC platform

    Our Pre-Sub returned no cybersecurity questions - the FDA agrees with our approach.

    Inflection point
    Series A
    Raise: $8M – $20M
    $200K – $500K
    2–3% of raise

    Pivotal study, 510(k) / De Novo / PMA prep, scale engineering.

    What to buy
    • Full eSTAR-ready cybersecurity package
    • Manual exploit-driven pen test (device + app + cloud + wireless)
    • Coordinated Vulnerability Disclosure program
    • Cybersecurity labeling + MDS² prep
    • Submission support + reviewer-letter response
    Skip

    Full-time CISO before postmarket scale

    Our cybersecurity package is reviewer-ready. Submission risk is contained.

    Series B
    Raise: $20M – $60M
    $500K – $1.5M / yr
    1–2% of raise

    Commercialization, postmarket scale-up, EU + global expansion.

    What to buy
    • Operational PSIRT (in-house lead + external surge)
    • Continuous SBOM monitoring + VEX program
    • Annual third-party pen test + per-release retests
    • EU MDR cybersecurity package (harmonized w/ FDA)
    • Tabletop exercises + IR readiness
    Skip

    Over-tooling - process maturity beats SaaS sprawl

    We have a postmarket cyber program with measurable SLAs - hospital procurement teams trust us.

    Series C+
    Raise: $60M+
    $1.5M – $5M+ / yr
    1–1.5% of opex of raise

    Multi-product portfolio, M&A, IPO-readiness.

    What to buy
    • Full-time CISO + product security org
    • M&A cybersecurity due diligence capability
    • Continuous compliance (FDA, EU MDR, CRA, HITRUST, SOC 2)
    • ML-specific monitoring for AI-enabled SaMD
    • Bug bounty program
    Skip

    Vanity certifications outside customer ask

    We're an acquirer's dream - clean posture, no skeletons in the SBOM.

    Five budget rules

    How to spend
    RULE 01
    Budget cyber as a % of the raise

    2–5% through Series A. Cheapest insurance against a 6-month FDA deficiency loop.

    RULE 02
    Front-load architecture decisions

    A $20K threat model in Pre-Seed prevents a $400K firmware re-architecture in Series A.

    RULE 03
    Use the FDA Pre-Sub - it's free

    A Q-Sub with cyber scope returns written FDA feedback in ~75 days. Highest-leverage spend in fundraising.

    RULE 04
    Buy outcomes, not headcount, until Series B

    Fractional / contract expertise tied to deliverables (threat model, pen test, SBOM, CVD).

    RULE 05
    Don't double-pay for FDA + EU evidence

    One harmonized package - same SBOM, same threat model, two filings. Saves 4–6 months.

    Don't say

    "We're spending $300K on a penetration test and SBOM tooling."

    Say

    "We're investing 3% of the round in an FDA-ready cybersecurity package - the same package now mandatory under the 2026 final guidance - to remove submission risk and be procurement-ready for the top 50 hospital systems on day one."

    Raising right now?
    30 minutes with a senior medical device security engineer. We'll size the right cyber line item for your round, device class and timeline.
    Book with Blue Goat
    Source: Blue Goat Cyber - Funding-Stage Cybersecurity Budget Guide
    § 06 - Post-mortem

    Why most MedTech startups never reach durable revenue.

    A working taxonomy of failure modes drawn from public MedTech wind-downs, FDA refuse-to-accept patterns and CB Insights / Silicon Valley Bank post-mortems. Read it before your next board meeting.

    № 01Commercial

    Reimbursement never materialised

    Founders build a device that works clinically but lacks a CPT code, payor coverage, or a credible cost-savings story. The hospital says yes; the CFO says no.

    № 02Regulatory

    Regulatory pathway misjudged

    A 510(k) becomes a De Novo. A De Novo becomes a PMA. Each escalation adds 18+ months and $5–15M unplanned burn.

    № 03Clinical

    Clinical evidence too thin to scale

    Pilot data convinced the seed round but cannot survive a peer-reviewed publication or a multi-site RCT. Sales stall at 12 hospitals.

    № 04Cyber

    Cybersecurity blocked clearance

    Since the FD&C Act §524B took effect (Mar 2023) and the FDA cyber guidance was finalised (Sep 2023, refreshed Feb 2026), connected-device submissions without an SBOM, threat model and SPDF evidence are subject to Refuse-to-Accept.

    № 05Team

    Founder-CEO outgrew the role

    The brilliant clinician-founder cannot scale ops, hire VPs, or manage a 60-person org. Boards routinely delay the transition past the point of no return.

    № 06Finance

    Capital efficiency collapsed

    Burn rate doubled before milestones were hit. Down rounds become unavoidable; the cap table cannibalises future raises.

    № 07IP

    IP exposed by a single weak claim

    Late-stage diligence discovers prior art, a defective continuation, or freedom-to-operate gaps in core geographies.

    The takeaway

    Three of the top four killers - reimbursement, regulatory, cyber - are solvable in pre-seed with the right diligence.

    Synthesised from CB Insights MedTech post-mortems, SVB Healthcare Investments & Exits reports, and FDA refuse-to-accept patterns.
    § 07 - The Founder Journey

    From napkin sketch to liquidity, in seven phases.

    The end-to-end MedTech founder map - what to build, who to raise from, what regulatory and cyber work to commission, and which resources actually move the needle at each phase. Median cadence: 8–10 years from concept to clearance.

    Discovery
    Months 0–6
    Concept
    Months 6–18
    Build
    Months 18–30
    Clearance
    Months 30–48
    Launch
    Months 48–66
    Scale
    Year 6–8
    Exit
    Year 8+
    1. Phase 01
      Discovery
      Months 0–6
      Funding
      Bootstrap / Friends & Family

      Find a clinical problem worth a company

      Work to do
      • Shadow 20+ procedures
      • Validate unmet need with 30 KOL interviews
      • Run a freedom-to-operate landscape scan
    2. Phase 02
      Concept
      Months 6–18
      Funding
      Pre-Seed · $250K–$1.5M

      Prototype + IP + regulatory hypothesis

      Work to do
      • Bench prototypes + design history file
      • Provisional + PCT filings
      • Pre-Sub strategy memo to FDA
      • Threat model + cyber risk register
    3. Phase 03
      Build
      Months 18–30
      Funding
      Seed · $1.5M–$5M

      MVP, first-in-human, regulatory pathway lock-in

      Work to do
      • Design freeze + V&V plan
      • First-in-human / feasibility IRB study
      • Quality system (ISO 13485) lite
      • STRIDE threat model + CycloneDX SBOM
    4. Phase 04
      Clearance
      Months 30–48
      Funding
      Series A · $8M–$20M

      Pivotal study + 510(k) / De Novo / PMA

      Work to do
      • Pivotal trial enrollment + readout
      • eSTAR submission + reviewer letters
      • Cybersecurity pre-market package
      • Reimbursement code strategy filed
    5. Phase 05
      Launch
      Months 48–66
      Funding
      Series B · $20M–$60M

      First 50 hospitals + EU MDR

      Work to do
      • Hire VP Sales + first 10 reps
      • EU MDR conformity + CE mark
      • MDS² + SOC 2 for hospital procurement
      • Postmarket surveillance + CVD program
    6. Phase 06
      Scale
      Year 6–8
      Funding
      Series C+ · $60M+

      Multi-product, international, indication expansion

      Work to do
      • TGA / PMDA / NMPA filings
      • M&A pipeline of complementary assets
      • Bug bounty + ML monitoring for SaMD
      • ISO 27001 / HITRUST
    7. Phase 07
      Exit
      Year 8+
      Funding
      IPO / Strategic acquisition

      Liquidity event

      Work to do
      • S-1 prep or strategic process
      • Cyber due diligence (acquirer ask)
      • Multi-year postmarket evidence package
      • Acquirer integration playbook
    In APAC and at the Concept or Build phase?
    MedTech Innovator APAC runs an annual accelerator with $350K+ in non-dilutive prizes, mentor access, and direct intros to strategics. Blue Goat Cyber is a sponsor.
    Apply to MedTech Innovator APAC
    § 08 - The Founder Playbook

    Everything else you'll need between rounds.

    A growing library of operator-grade templates and frameworks, written by people who have brought devices to market.

    Stage-Gate Roadmap

    Map every funding round to a value inflection: bench → animal → first-in-human → pivotal → clearance.

    • Each round should retire one specific class of risk (technical, clinical, regulatory, commercial).
    • Investor 'unlock' = the readout that justifies the next round at a 2-3× step-up.
    • Plan milestones at 75% confidence - boards forgive a 3-month slip, not a missed gate.
    Stanford Biodesign Stage-Gate

    FDA Pre-Sub Templates

    Q-Sub letter structure, expected questions, and the cybersecurity addendum reviewers expect in 2026.

    • Submit Pre-Sub before Series A - written FDA feedback in ~75 days, fully free.
    • Frame 3-5 specific questions, not open-ended ones. 'Is this an acceptable predicate?' beats 'thoughts?'
    • Always include cyber scope now: threat model summary + intended SBOM format.
    FDA Q-Sub Program

    KOL & Advisor Mapping

    How to recruit 3 KOLs by Series A without diluting your cap table or your scientific narrative.

    • Tier 1 KOL = will publish on your device. Tier 2 = will speak at your investor day. Tier 3 = will demo it.
    • Equity ranges: 0.10–0.25% per KOL advisor, 4-yr vesting, 1-yr cliff. Cash retainer optional.
    • Avoid 'rented' KOLs: ones who advise 8 startups in your space provide zero defensibility.
    AdvaMed Code on KOL Interactions

    Clinical Study Design

    Choosing endpoints payors will pay for, not just endpoints regulators will clear.

    • FDA primary endpoint ≠ payor-facing endpoint. Build in both from study design day one.
    • Cost-offset endpoints (LOS, readmission, complication rate) win reimbursement conversations.
    • Pre-register on ClinicalTrials.gov even for feasibility - silence later reads as a failed trial.
    ClinicalTrials.gov Registration

    Reimbursement Playbook

    CPT pathways, transitional pass-through codes, and what 'breakeven per procedure' really means.

    • Existing CPT > Category III > new Category I. Know your path before Series A or you'll pivot it later.
    • TPT (transitional pass-through) for inpatient devices buys you 2-3 yrs of extra hospital margin - critical for adoption.
    • Hospital must net-positive at the procedure level on day one. 'Long-term savings' arguments lose to the CFO every time.
    AdvaMed Reimbursement Resources

    APAC Market Entry

    TGA, PMDA, NMPA - sequencing approvals across Australia, Japan and China for MedTech innovators.

    • Australia (TGA) is often the fastest first market - 6-9 months, English regulator, real revenue.
    • Japan (PMDA) rewards thorough submissions; once cleared, premium pricing and durable adoption.
    • China (NMPA) usually requires local clinical data - partner with a CRO + distributor before filing.
    • MedTech Innovator APAC provides direct intros to TGA-savvy mentors and Japanese strategics.
    MedTech Innovator APAC
    § 09 - Programs & Resources

    The MedTech founder's starter kit.

    A curated index of the accelerators, regulators, communities, books and vendors that meaningfully move a MedTech startup forward. Featured listings are sponsors or programs we've personally vetted with founders.

    Accelerators & Programs

    Apply early - the application alone forces narrative discipline.

    MedTech Innovator APAC

    APAC · Free · Annual cohort

    Asia-Pacific accelerator for medical-device startups. Mentor network, partner intros (J&J, Medtronic, Olympus), and $350K+ in non-dilutive prizes. Blue Goat Cyber sponsors the cybersecurity track.

    MedTech Innovator (Global)

    Global · Free · Equity-free

    World's largest non-dilutive accelerator for MedTech. 4-month curriculum, 750+ alumni, $7M+ awarded annually.

    Y Combinator

    US · 7% equity

    $500K standard deal. Strong alumni network, but MedTech is a minority of the batch - pick partners with hardware/regulated experience.

    Techstars Healthcare

    US/Global · 6% equity · $120K

    Multiple healthcare-focused programs (Mayo Clinic, Cedars-Sinai, UnitedHealthcare). Strong hospital channel access.

    JLABS (Johnson & Johnson Innovation)

    Global · Lab access

    No-strings-attached lab residencies in 13 cities. Excellent for hardware founders who need wet-lab + electronics space.

    Plug and Play Health

    Global · Equity-free

    Corporate-sponsored matchmaking with hospital systems and pharma. Less curriculum, more pilot opportunities.

    Regulatory Bodies & Standards

    Bookmark all of these. Read the guidance documents, not the summaries.

    FDA CDRH (Devices)

    USA

    510(k), De Novo, PMA pathways. Use the Pre-Sub program - it's free and returns written feedback in ~75 days.

    FDA Pre-Sub (Q-Sub) Program

    USA · Free

    The single highest-leverage spend in your fundraising lifecycle, because it's $0.

    FDA 2026 Cybersecurity Guidance

    PDF

    Mandatory cybersecurity content for premarket submissions of connected devices. SBOM, threat model, postmarket plan.

    EU MDR (Regulation 2017/745)

    EU

    European medical device regulation. Notified Body conformity assessment + UDI + EUDAMED.

    TGA (Therapeutic Goods Administration)

    Australia

    Australia's regulator. Often the fastest first market for APAC-headquartered startups.

    PMDA (Japan)

    Japan

    Japan's MHLW pathway. Long, structured, predictable - and a meaningful market for high-end devices.

    NMPA (China)

    China

    China's regulator. Local clinical evidence usually required - partner with a CRO early.

    ISO 13485 (QMS)

    Standard

    Quality management system standard. Required for CE mark, expected by FDA, demanded by acquirers.

    ISO 14971 (Risk Mgmt)

    Standard

    Risk management for medical devices. Maps directly to your design history file and cyber risk register.

    AAMI TIR57 (Cyber)

    Standard

    Cybersecurity risk management for medical devices - the technical companion to FDA's premarket guidance.

    Communities & Networks

    Where MedTech founders actually compare notes.

    AdvaMed

    Trade body

    US trade association. Best-in-class regulatory and reimbursement policy briefs, plus working groups on cybersecurity and AI/ML.

    MedTech Europe

    Trade body · EU

    European industry voice. Track EU MDR implementation guidance and EU AI Act medical device carve-outs here.

    Stanford Biodesign

    Methodology

    The reference methodology for need identification. Free curriculum, fellowship program, and global network of practitioners.

    AAMI

    Standards

    Association for the Advancement of Medical Instrumentation. Standards body + community for QA, regulatory and cyber engineers.

    Health-ISAC (Cyber)

    Cyber

    Information Sharing & Analysis Center for healthcare cybersecurity. Threat intel feed worth subscribing to from Series B onward.

    r/medicaldevices

    Community

    Surprisingly high-signal subreddit. Regulatory questions get real answers from practicing engineers.

    Books & Long-Form Reading

    The dozen texts every MedTech founder eventually reads.

    Biodesign: The Process of Innovating Medical Technologies

    Zenios, Makower, Yock

    Stanford Biodesign textbook. The canonical end-to-end MedTech founder reference.

    The Lean Startup

    Eric Ries

    Yes, generic - but the build-measure-learn loop is essential discipline for hardware founders who default to over-building.

    Crossing the Chasm

    Geoffrey Moore

    Required reading for the IDN sales motion. The chasm between early adopter clinicians and mainstream procurement is real.

    Medical Device Marketing

    Terri Wells

    Practical reimbursement, KOL, and channel strategy. Dated examples, timeless framework.

    Hacking Healthcare

    Trotter & Uhlman

    Decent primer on the US healthcare delivery system, payors, and where MedTech actually fits in the workflow.

    FDA's CDRH Learn (free courses)

    Free · Video

    Free FDA-produced video tutorials on every submission pathway. Watch before your Pre-Sub.

    Tools, Tooling & Vendors

    Categorically the things you'll buy or trial - not endorsements.

    Greenlight Guru (eQMS)

    QMS

    Purpose-built electronic QMS for medical device companies. Most-used choice for ISO 13485 by Series A.

    Jama Connect (Requirements)

    ALM

    Requirements + traceability + V&V evidence. Painful learning curve, but auditors love the output.

    Medcrypt (Device Security)

    Cyber

    Cybersecurity tooling specifically for medical devices - SBOM, vuln management, cryptographic agility.

    Blue Goat Cyber

    Cyber · Services

    Senior medical device cybersecurity services - threat modelling, pen testing, FDA premarket package, postmarket. Sponsor of MedTech Innovator APAC.

    CycloneDX (SBOM format)

    Open standard

    Open-source SBOM standard. The format FDA expects. Generate it from your CI pipeline, not by hand.

    Crunchbase Pro / PitchBook

    Data

    Investor research and round benchmarking. Pricey, worth it for Series A onward.

    The Weekly Brief

    Tuesdays. 12 minutes. Every funding round, regulatory note and cyber alert that mattered.

    Built for MedTech founders, operators and investors across APAC, the US and EU. Free, no spam, unsubscribe in one click.

    By subscribing you agree to our editorial terms. We never sell data.